23 Feb Orchard Therapeutics
Leslie Meltzer, Ph.D., Chief Medical Officer
Oct. 11 | 2:15pm | Aseptic Technologies Ballroom
Boston, MA
(NASDAQ: ORTX)
At Orchard Therapeutics, our vision is to end the devastation caused by genetic and other severe diseases. We aim to do this by discovering, developing and commercializing new treatments that tap into the curative potential of hematopoietic stem cell (HSC) gene therapy. In this approach, a patient’s own blood stem cells are genetically modified outside of the body and then reinserted, with the goal of correcting the underlying cause of disease in a single treatment. Orchard was founded in 2015—but our roots run deeper, going back to some of the first research and clinical development involving HSC gene therapy. Today, Orchard is advancing a pipeline spanning pre-clinical, clinical and commercial stage HSC gene therapies designed to address serious diseases where the burden is immense for patients, families and society and current treatment options are limited or do not exist.
